- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic strategies to target RAS-mutant cancers
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 11, Pages 709-720
Publisher
Springer Nature America, Inc
Online
2018-10-01
DOI
10.1038/s41571-018-0105-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling
- (2018) Michael C. Burns et al. ANALYTICAL BIOCHEMISTRY
- c-RAF Ablation Induces Regression of Advanced Kras/Trp 53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
- (2018) Manuel Sanclemente et al. CANCER CELL
- KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
- (2018) Chiara Ambrogio et al. CELL
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics
- (2018) Dominic Esposito et al. SEMINARS IN CANCER BIOLOGY
- Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer
- (2018) Mehlika Hazar-Rethinam et al. Cancer Discovery
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- Differential Effector Engagement by Oncogenic KRAS
- (2018) Tina L. Yuan et al. Cell Reports
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Spatiotemporal Analysis of K-Ras Plasma Membrane Interactions Reveals Multiple High Order Homo-oligomeric Complexes
- (2017) Suparna Sarkar-Banerjee et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
- (2017) Marco Jost et al. MOLECULAR CELL
- Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer
- (2017) M Pek et al. ONCOGENE
- Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
- (2017) Andrew M. Waters et al. Science Signaling
- Survival of pancreatic cancer cells lacking KRAS function
- (2017) Mandar Deepak Muzumdar et al. Nature Communications
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells
- (2017) Timothy D. Martin et al. Cell Reports
- A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
- (2017) Grace R. Anderson et al. Cell Reports
- Kras and Tumor Immunity: Friend or Foe?
- (2017) Jane Cullis et al. Cold Spring Harbor Perspectives in Medicine
- Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
- (2017) Andrew M. Waters et al. Science Signaling
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
- (2017) Mark Merchant et al. PLoS One
- Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
- (2016) Tikvah K. Hayes et al. CANCER CELL
- High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells
- (2016) Thomas Horn et al. CANCER RESEARCH
- Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
- (2016) D. Oddo et al. CANCER RESEARCH
- A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
- (2016) Sai Krishna Athuluri-Divakar et al. CELL
- Covalent targeting of acquired cysteines in cancer
- (2016) Marieke Visscher et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- RAS isoforms and mutations in cancer at a glance
- (2016) G. Aaron Hobbs et al. JOURNAL OF CELL SCIENCE
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Dissecting Therapeutic Resistance to ERK Inhibition
- (2016) S. Jha et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit
- (2016) Daniel A. Ritt et al. MOLECULAR CELL
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Inhibition of RAS function through targeting an allosteric regulatory site
- (2016) Russell Spencer-Smith et al. Nature Chemical Biology
- Putting the brakes on KRAS-G12C nucleotide cycling
- (2016) Lydia Shipman NATURE REVIEWS DRUG DISCOVERY
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- Protein prenylation: unique fats make their mark on biology
- (2016) Mei Wang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Drugging the Undruggable Ras — Immunotherapy to the Rescue?
- (2016) Carl H. June NEW ENGLAND JOURNAL OF MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- COSMIC: somatic cancer genetics at high-resolution
- (2016) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Identification of pyrazolopyridazinones as PDEδ inhibitors
- (2016) Björn Papke et al. Nature Communications
- Progress on Covalent Inhibition of KRASG12C
- (2016) K. D. Westover et al. Cancer Discovery
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
- (2016) Eliza Vakana et al. Oncotarget
- Phenotypic Characterization of a Comprehensive Set of MAPK1 /ERK2 Missense Mutants
- (2016) Lisa Brenan et al. Cell Reports
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
- (2015) N. Jacque et al. BLOOD
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
- (2015) Maria Romina Girotti et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance
- (2015) Ursula Germann et al. CANCER RESEARCH
- Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
- (2015) E. K. Ziemke et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Metabolic Dependencies in RAS-Driven Cancers
- (2015) A. C. Kimmelman CLINICAL CANCER RESEARCH
- RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
- (2015) J. Downward CLINICAL CANCER RESEARCH
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Regulation of RAF protein kinases in ERK signalling
- (2015) Hugo Lavoie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
- (2015) Xiaolin Nan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
- (2015) J. Yun et al. SCIENCE
- Adoptive cellular therapy: A race to the finish line
- (2015) Carl H. June et al. Science Translational Medicine
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
- (2015) L. G. Ahronian et al. Cancer Discovery
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
- (2015) Q. J. Wang et al. Cancer Immunology Research
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
- (2015) Jorge Franco et al. Oncotarget
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
- (2014) Piro Lito et al. CANCER CELL
- Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response
- (2014) Elda Grabocka et al. CANCER CELL
- ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
- (2014) E. M. Goetz et al. CANCER RESEARCH
- Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers
- (2014) A. N. Hata et al. CANCER RESEARCH
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
- (2014) Ian R. Watson et al. CANCER RESEARCH
- Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
- (2014) S. Okumura et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer
- (2014) G. L. Johnson et al. CLINICAL CANCER RESEARCH
- Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
- (2014) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Mitogen-activated Protein Kinase (MAPK) Hyperactivation and Enhanced NRAS Expression Drive Acquired Vemurafenib Resistance in V600E BRAF Melanoma Cells
- (2014) Michael Lidsky et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis
- (2014) Katja Schuster et al. MOLECULAR CANCER RESEARCH
- Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3
- (2014) Asli Muvaffak et al. MOLECULAR CANCER RESEARCH
- Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
- (2014) M. I. Gross et al. MOLECULAR CANCER THERAPEUTICS
- Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
- (2014) M. R. Junttila et al. MOLECULAR CANCER THERAPEUTICS
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vertical inhibition of the MAPK pathway enhances therapeutic responses inNRAS-mutant melanoma
- (2014) Vito W. Rebecca et al. Pigment Cell & Melanoma Research
- H-Ras forms dimers on membrane surfaces via a protein-protein interface
- (2014) W.-C. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C
- (2014) J. C. Hunter et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
- (2014) Michael C. Burns et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Systematic identification of signaling pathways with potential to confer anticancer drug resistance
- (2014) C. A. Martz et al. Science Signaling
- Dimerization Opens New Avenues into Ras Signaling Research
- (2014) E. Santos Science Signaling
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
- (2014) Z. Zhu et al. Cancer Discovery
- Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
- (2014) C. E. Burd et al. Cancer Discovery
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- Ral GTPases in tumorigenesis: Emerging from the shadows
- (2013) David F. Kashatus EXPERIMENTAL CELL RESEARCH
- Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
- (2013) Cosimo Commisso et al. NATURE
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
- (2013) Jaekyoung Son et al. NATURE
- Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
- (2013) Gunther Zimmermann et al. NATURE
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
- (2013) C. Posch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
- (2012) Yuliya Pylayeva-Gupta et al. CANCER CELL
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model
- (2012) H. Y. Chow et al. CANCER RESEARCH
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
- (2012) M. Martinez-Garcia et al. CLINICAL CANCER RESEARCH
- Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
- (2012) Meredith A. Collins et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- KRASG12D- and BRAFV600E-Induced Transformation of Murine Pancreatic Epithelial Cells Requires MEK/ERK-Stimulated IGF1R Signaling
- (2012) V. A. Appleman et al. MOLECULAR CANCER RESEARCH
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
- (2012) Margaret K. Callahan et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
- (2012) T. Luo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MAP Kinase Pathways
- (2012) D. K. Morrison Cold Spring Harbor Perspectives in Biology
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
- (2012) Eric A. Collisson et al. Cancer Discovery
- Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
- (2012) Amy Young et al. Cancer Discovery
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
- (2011) Rafael B. Blasco et al. CANCER CELL
- STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells
- (2011) C. Babij et al. CANCER RESEARCH
- Pancreatic cancers require autophagy for tumor growth
- (2011) S. Yang et al. GENES & DEVELOPMENT
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth
- (2011) D. Gaglio et al. Molecular Systems Biology
- Regulating the regulator: post-translational modification of RAS
- (2011) Ian M. Ahearn et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Resistance to MEK Inhibitors: Should We Co-Target Upstream?
- (2011) P. I. Poulikakos et al. Science Signaling
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
- (2010) Qing-Bai She et al. CANCER CELL
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer
- (2010) M. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
- (2008) Kevin M Haigis et al. NATURE GENETICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More